logo dark logo light logo
  • Solutions
    • Modelling and Simulation
      • Mechanism of Action Modelling
      • Exposure Response Modelling
      • Translational Modelling
      • Tumour Growth Inhibition Modelling
      • Population PK and NCA
      • PBPK Modelling
      • Clinical Trial Simulation
    • Biostatistics
    • Data Science & Bioinformatics
  • Virtual Tumour
  • Precision Oncology
  • Resources
    • Scientific Content
    • Investor Content
    • FAQs
  • News
    • All News
    • Investor News / RNS
    • Blog
    • Events
  • AIM Rule 26
    • Share Information
    • Investor News / RNS
    • Board of Directors
    • Advisors
    • Corporate Governance
    • Financial Reports
    • Corporate Documents
    • Registration
  • About Us
    • Partners
    • Team
    • Careers
  • Contact
logo dark logo light logo
  • Solutions
    • Modelling and Simulation
      • Mechanism of Action Modelling
      • Exposure Response Modelling
      • Translational Modelling
      • Tumour Growth Inhibition Modelling
      • Population PK and NCA
      • PBPK Modelling
      • Clinical Trial Simulation
    • Biostatistics
    • Data Science & Bioinformatics
  • Virtual Tumour
  • Precision Oncology
  • Resources
    • Scientific Content
    • Investor Content
    • FAQs
  • News
    • All News
    • Investor News / RNS
    • Blog
    • Events
  • AIM Rule 26
    • Share Information
    • Investor News / RNS
    • Board of Directors
    • Advisors
    • Corporate Governance
    • Financial Reports
    • Corporate Documents
    • Registration
  • About Us
    • Partners
    • Team
    • Careers
  • Contact
mobile-logo
  • Solutions
    • Modelling and Simulation
      • Mechanism of Action Modelling
      • Exposure Response Modelling
      • Translational Modelling
      • Tumour Growth Inhibition Modelling
      • Population PK and NCA
      • PBPK Modelling
      • Clinical Trial Simulation
    • Biostatistics
    • Data Science & Bioinformatics
  • Virtual Tumour
  • Precision Oncology
  • Resources
    • Scientific Content
    • Investor Content
    • FAQs
  • News
    • All News
    • Investor News / RNS
    • Blog
    • Events
  • AIM Rule 26
    • Share Information
    • Investor News / RNS
    • Board of Directors
    • Advisors
    • Corporate Governance
    • Financial Reports
    • Corporate Documents
    • Registration
  • About Us
    • Partners
    • Team
    • Careers
  • Contact
 

Investor Content

Explore our Investor Content

Our Investor Hub offers easy access to company updates such as latest financial reports, board announcements and investor presentations, to keep you informed of our progress.

Investor presentation – Company update

Investor

Investor presentation – Full Year Results and Company update

Investor

Investor presentation – Interim Results and Company update

Investor

Investor presentation – Board Changes

Investor

Investor presentation – Company update

Investor

Investor presentation – Trading and company update

Investor

Trading update

Investor

Interim results presentation for the six months ended 31 December 2021

Investor

Video of full year results presentation 2021

Investor

Slide presentation of results for year ended 30 June 2021

Investor
logo

Physiomics Plc

Bee House

140 Eastern Avenue

Milton Park

Oxfordshire, OX14 4SB

United Kingdom

Email: info@physiomics.co.uk

Phone: +44 (0) 1235 841575

Quick Links

  • About
  • R&D Services
  • Resources
  • All News
  • Blog
  • AIM Rule 26
  • Legal & Privacy Policy
  • Sitemap
  • Contact
Newsletter
Receive news and updates from Physiomics. Select your interest below:
Corporate
Scientific

Copyright © Physiomics Plc 2025. Physiomics® is a registered trademark of Physiomics Plc.